|
Post by casualinvestor on Apr 17, 2018 8:48:54 GMT -5
Assuming you are right that some of the numbers are off, are you suggesting that there isn't enough insurance available for even a 1% market penetration? No, I'm just suggesting that you can't rely on formularytracker to assess the current insurance situation. You can tell the significance of insurance by looking at otherottawaguy's posts of competitors sales -- Apidra 6,693 $5.16m/Novalog 137,000 $133m/Humalog 155,000 $144m. Despite being cheaper retail than either humalog or novolog, Apidra coverage is almost as bad as afrezza. Even if afrezza caught up with apidra, would it be enough to for Mannkind to break even? $5M/week would be, conservatively, $11M/month revenue even without considering that cost/unit would go down a bit at that volume. More than enough for Mannkind to break even. I think the break even point is somewhere between $3M/week and $4M/week. At ~$1M/week, we hit guidance for the year. Note that is 2x the sales/week from Q4
|
|